Terminated PHASE1 INTERVENTIONAL 1-arm NCT00621283

Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population

RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population

Sponsor: Massachusetts General Hospital

Conditions Acute Recurrent Pancreatitis Chronic Pancreatitis

Interventions RG1068 (Synthetic Human Secretin)

Updated 6 times since 2017 Last updated: Jan 27, 2009 Started: Feb 29, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor patient enrollment due to logistical issues

Other terminated trials from Massachusetts General Hospital

See all terminations from Massachusetts General Hospital

A PHASE1 clinical study on Acute Recurrent Pancreatitis and Chronic Pancreatitis, this trial is terminated or withdrawn. The trial is conducted by Massachusetts General Hospital and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States